Learn about our rebrand Learn More
Washington, DC (January 27, 2025) – The Melanoma Research Foundation (MRF), the largest independent organization devoted to melanoma, is excited to announce the official ...
Uveal Melanoma (UM), a deadly cancer arising in the eye, is the most common eye cancer in adults. Early detection of UM is important due to the cancer’s ability to spread...
The phenomenon of “RNA editing” is a relatively recent discovery with exciting implications. RNA editing is a process that modifies the sequence of RNA after it is copi...
A major reason that T cell-based melanoma immunotherapies can fail, either initially or after a period of treatment, is due to mutations that result in CD8+ T cells being i...
Metastatic melanoma is one of the most aggressive, and complex cancers with a 35% 5-year survival rate. Therapies using T cells that are genetically engineered to express t...
For decades, cancer initiation and progression are thought to occur gradually through small mutational changes in its DNA. After natural selection, winning variants that ha...
Patients with mucosal melanoma are likely to have poor outcomes with current standard-of-care treatment options. The reasons are multifactorial but include difficulty obtai...
Melanoma is the most aggressive form of skin cancer. Although progress has been made for advanced melanoma patients with 13 new FDA-approved therapies since 2011, resistanc...
Apr 26, 2025 - Apr 27, 2025
